甲地孕酮下调IL-6提高晚期肿瘤患者放化疗的耐受性

Megestrol Improved Toleration to Radiotherapy and Chemotherapy for Patients with Advanced Cancer through Descending Level of Serum IL-6

目的:观察甲地孕酮对晚期肿瘤患者血清IL-6水平及放化疗耐受性的影响。方法:非小细胞肺癌36例,小细胞肺癌10例,鼻咽癌20例,随机分为治疗组(放化疗加甲地孕酮160mg/d)和对照组(单纯放化疗)各33例。分别观察治疗期间血清IL-6水平及放化疗所致消化道反应,血液毒性,体重,食欲,生活质量状态等的变化。结果:治疗组的患者血清的IL-6水平明显降低(P<0.001),消化道反应和血液毒性发生率低于对照组(P<0.05),生活质量改善优于对照组(P<0.01),未见甲地孕酮所致的严重毒副作用。结论:甲地孕酮通过下调血清IL-6水平提高晚期肿瘤患者对放化疗耐受性。

Objective To investigate the effects of megestrol on serum IL-6 level and toleration to the radiotherapy and chemotherapy of the patients with advanced cancer.Methods 36 cases of non-small-cell lung cancer,10 cases of small cell lung cancer,20 cases of nasopharyngeal cancer.Randomly divide them into two groups:treat group(radiotherapy and chemotherapy plus treatment wih 160mg/d of megestrol) and control group(radiotherapy and chemotherapy alone).The serum IL-6 level,the alimentary tract reaction,the blood poison,weight,appetite and the life quality during therapy are all carefully watched.Results After the treatment, the patient's serum IL-6 level dropped remarkably(P<0.001).Incidence of the alimentary tract reaction and blood poison of the treat group is lower than the control group(P<0.05)while the improvement of life quality of the former is better than the latter(P<0.01).There is no evidence of serious side effects of megestrol.Conclusion For the patients with advanced cancer,megestrol can improve their toleration to the radiotherapy and chemotherapy by decreasing serum IL-6 level.